Arrowhead Pharmaceuticals, Inc. (ARWR) News
Filter ARWR News Items
ARWR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARWR News Highlights
- ARWR's 30 day story count now stands at 4.
- Over the past 19 days, the trend for ARWR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ARWR are CFB, RNA and ST.
Latest ARWR News From Around the Web
Below are the latest news stories about ARROWHEAD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARWR as an investment opportunity.
Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 SharesArrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Anzalone sold 12,000 shares of the company's stock on December 20, 2023, according to a recent SEC filing. |
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney DiseasePASADENA, Calif., December 21, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement mediated renal disease, such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-st |
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferencePASADENA, Calif., December 20, 2023--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT. |
ARWR: Updates on Plozasiran and Zodasiran at AHA 2023…By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Updated Clinical Data for Cardiometabolic Candidates Presented at AHA 2023 On November 13, 2023, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced new clinical data for the Phase 2 SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) were presented at the American |
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript November 29, 2023 Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vince […] |
Q4 2023 Arrowhead Pharmaceuticals Inc Earnings CallQ4 2023 Arrowhead Pharmaceuticals Inc Earnings Call |
Arrowhead Pharmaceuticals Inc Reports Fiscal 2023 Year-End ResultsFinancial Highlights and Recent Developments |
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End ResultsPASADENA, Calif., November 29, 2023--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023. The company is hosting a conference call today, November 29, 2023, at 4:30 p.m. ET to discuss the results. |
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic DystrophyPASADENA, Calif., November 28, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. |
Insider Sell Alert: Chief Medical Officer Martin San Sells 19,700 Shares of Arrowhead ...Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has recently witnessed a significant insider sell by its Chief Medical Officer, Martin San. |